Is the ChAdOx1 Vaccine Safe and Immunogenic as Prophylactic Measure Against the Lethal Human-Coronaviruses? A Systematic Review

Q3 Medicine

Acta medica Iranica Pub Date : 2023-07-12 DOI:10.18502/acta.v61i4.13169

Andréia Michelle Alves Cunha de Alcântara, Ivan de Alcântara Barbosa Barros, Luiz Paulo de Souza Prazeres, Ivan de Alcântara Barbosa Barros, Maria Mascena Diniz Maia, P. R. Eleutério de Souza

{"title":"Is the ChAdOx1 Vaccine Safe and Immunogenic as Prophylactic Measure Against the Lethal Human-Coronaviruses? A Systematic Review","authors":"Andréia Michelle Alves Cunha de Alcântara, Ivan de Alcântara Barbosa Barros, Luiz Paulo de Souza Prazeres, Ivan de Alcântara Barbosa Barros, Maria Mascena Diniz Maia, P. R. Eleutério de Souza","doi":"10.18502/acta.v61i4.13169","DOIUrl":null,"url":null,"abstract":"Knowledge of other Coronaviruses has contributed to the development of a vaccine for the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). As soon as the genetic sequence of SARS-CoV-2 was released, intense global activity around different vaccine platform technologies started. Among these platforms, the viral vectored chimpanzee adenovirus Oxford1 (ChAdOx1)-previously studied for various indications, including for the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) vaccine, and currently is adapted for the ChAdOx1 nCoV-19 (novel Coronavirus-19). Therefore, this systematic review aimed to investigate the potential of the ChAdOx1 platform for the development of a vaccine for SARS-CoV and MERS-CoV, the Lethal Human-Coronaviruses (Lh-CoVs). For this purpose, a highly sensitive literary search was conducted through electronic databases that reached 1,445 related articles, of which, eight articles were elected according to previous eligibility criteria. The gathering of the articles demonstrated that the previous approaches, referring to the ChAdox1 platform, have contributed to the development of vaccines against Lh-CoVs and, that thus far, ChAdOx1 (nCoV-19 and MERS) vaccines are safe and immunogenic. However, it is important to emphasize that further studies are needed to ensure the effectiveness of vaccines in humans.","PeriodicalId":6946,"journal":{"name":"Acta medica Iranica","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta medica Iranica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/acta.v61i4.13169","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Knowledge of other Coronaviruses has contributed to the development of a vaccine for the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). As soon as the genetic sequence of SARS-CoV-2 was released, intense global activity around different vaccine platform technologies started. Among these platforms, the viral vectored chimpanzee adenovirus Oxford1 (ChAdOx1)-previously studied for various indications, including for the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) vaccine, and currently is adapted for the ChAdOx1 nCoV-19 (novel Coronavirus-19). Therefore, this systematic review aimed to investigate the potential of the ChAdOx1 platform for the development of a vaccine for SARS-CoV and MERS-CoV, the Lethal Human-Coronaviruses (Lh-CoVs). For this purpose, a highly sensitive literary search was conducted through electronic databases that reached 1,445 related articles, of which, eight articles were elected according to previous eligibility criteria. The gathering of the articles demonstrated that the previous approaches, referring to the ChAdox1 platform, have contributed to the development of vaccines against Lh-CoVs and, that thus far, ChAdOx1 (nCoV-19 and MERS) vaccines are safe and immunogenic. However, it is important to emphasize that further studies are needed to ensure the effectiveness of vaccines in humans.

查看原文本刊更多论文

ChAdOx1疫苗作为针对致命人类冠状病毒的预防措施是否安全且具有免疫原性？系统综述

对其他冠状病毒的了解有助于开发严重急性呼吸综合征-冠状病毒-2 (SARS-CoV-2)疫苗。SARS-CoV-2的基因序列一经公布，全球就开始围绕不同的疫苗平台技术展开激烈的活动。在这些平台中，病毒载体黑猩猩腺病毒牛津1 (ChAdOx1)-先前研究用于各种适应症，包括用于中东呼吸综合征冠状病毒(MERS-CoV)疫苗，目前适用于ChAdOx1 nCoV-19(新型冠状病毒-19)。因此，本系统综述旨在探讨ChAdOx1平台在SARS-CoV和MERS-CoV(致命的人类冠状病毒)疫苗开发中的潜力。为此目的，通过电子数据库进行了高度敏感的文献检索，检索了1 445篇相关文章，其中8篇文章是根据以前的资格标准选出的。文章的收集表明，先前的方法(参考ChAdox1平台)有助于开发针对lh - cov的疫苗，并且到目前为止，ChAdox1 (nCoV-19和MERS)疫苗是安全的和免疫原性的。然而，必须强调的是，需要进一步的研究来确保疫苗对人类的有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta medica Iranica Medicine-Medicine (all)

CiteScore

0.70

自引率

0.00%

发文量

审稿时长

18 weeks

期刊介绍： ACTA MEDICA IRANICA (p. ISSN 0044-6025; e. ISSN: 1735-9694) is the official journal of the Faculty of Medicine, Tehran University of Medical Sciences. The journal is the oldest scientific medical journal of the country, which has been published from 1960 onward in English language. Although it had been published quarterly in the past, the journal has been published bimonthly (6 issues per year) from the year 2004. Acta Medica Iranica it is an international journal with multidisciplinary scope which publishes original research papers, review articles, case reports, and letters to the editor from all over the world. The journal has a wide scope and allows scientists, clinicians, and academic members to publish their original works in this field.